This HTML5 document contains 109 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00330/identifier/national-drug-code-directory/
n26http://linked.opendata.cz/resource/AHFS/
n18http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n27http://linked.opendata.cz/resource/drugbank/dosage/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00330/identifier/chebi/
n16http://bio2rdf.org/drugbank:
n9http://linked.opendata.cz/resource/drugbank/drug/DB00330/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n10http://linked.opendata.cz/resource/drugbank/drug/DB00330/identifier/pharmgkb/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00330/identifier/kegg-compound/
n14http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n15http://linked.opendata.cz/resource/drugbank/medicinal-product/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00330/identifier/bindingdb/
owlhttp://www.w3.org/2002/07/owl#
n17http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n20http://www.drugs.com/cdi/
n24http://www.rxlist.com/cgi/generic2/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00330/identifier/drugbank/
n7http://linked.opendata.cz/resource/atc/
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00330
rdf:type
n3:Drug
n3:description
An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863)
n3:dosage
n27:271B5651-363D-11E5-9242-09173F13E4C5 n27:271B5652-363D-11E5-9242-09173F13E4C5 n27:271B5653-363D-11E5-9242-09173F13E4C5 n27:271B5654-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
In patients with normal renal function, 3 to 4 hours. In patients with impaired renal function, up to 8 hours.
n3:indication
For use, as an adjunct, in the treatment of pulmonary tuberculosis.
n3:manufacturer
n4:271B5648-363D-11E5-9242-09173F13E4C5 n4:271B564B-363D-11E5-9242-09173F13E4C5 n4:271B5649-363D-11E5-9242-09173F13E4C5 n4:271B564A-363D-11E5-9242-09173F13E4C5
owl:sameAs
n14:DB00330 n16:DB00330
dcterms:title
Ethambutol
adms:identifier
n9:Ethambutol n10:PA164784021 n11:50204422 n12:4877 n21:C06984 n22:0555-0923-02 n23:DB00330
n3:mechanismOfAction
Ethambutol inhibits arabinosyl transferases which is involved in cell wall biosynthesis. By inhibiting this enzyme, the bacterial cell wall complex production is inhibited. This leads to an increase in cell wall permeability.
n3:packager
n4:271B563E-363D-11E5-9242-09173F13E4C5 n4:271B5633-363D-11E5-9242-09173F13E4C5 n4:271B5634-363D-11E5-9242-09173F13E4C5 n4:271B5631-363D-11E5-9242-09173F13E4C5 n4:271B5632-363D-11E5-9242-09173F13E4C5 n4:271B5637-363D-11E5-9242-09173F13E4C5 n4:271B5638-363D-11E5-9242-09173F13E4C5 n4:271B5635-363D-11E5-9242-09173F13E4C5 n4:271B5636-363D-11E5-9242-09173F13E4C5 n4:271B5630-363D-11E5-9242-09173F13E4C5 n4:271B5643-363D-11E5-9242-09173F13E4C5 n4:271B5644-363D-11E5-9242-09173F13E4C5 n4:271B5641-363D-11E5-9242-09173F13E4C5 n4:271B5642-363D-11E5-9242-09173F13E4C5 n4:271B5647-363D-11E5-9242-09173F13E4C5 n4:271B5645-363D-11E5-9242-09173F13E4C5 n4:271B5646-363D-11E5-9242-09173F13E4C5 n4:271B563B-363D-11E5-9242-09173F13E4C5 n4:271B563C-363D-11E5-9242-09173F13E4C5 n4:271B5639-363D-11E5-9242-09173F13E4C5 n4:271B563A-363D-11E5-9242-09173F13E4C5 n4:271B563F-363D-11E5-9242-09173F13E4C5 n4:271B5640-363D-11E5-9242-09173F13E4C5 n4:271B563D-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
During the 24-hour period following oral administration of ethambutol hydrochloride approximately 50 percent of the initial dose is excreted unchanged in the urine, while an additional 8 to 15 percent appears in the form of metabolites. From 20 to 22 percent of the initial dose is excreted in the feces as unchanged drug.
n3:synonym
EMB (S,S)-Ethambutol (+)-2,2'-(ethylenediimino)di-1-butanol S,S-Ethambutol Etambutol Ethambutolum (2S,7S)-2,7-Diethyl-3,6-diazaoctane-1,8-diol (+)-N,N'-bis(1-(hydroxymethyl)propyl)ethylenediamine Ethambutol (+)-S,S-ethambutol Etambutolo (+)-ethambutol
n3:toxicity
The most commonly recognized toxic effect of ethambutol is optic neuropathy, which generally is considered uncommon and reversible in medical literature. Other side effects that have been observed are pruritus, joint pain, gastrointestinal upset, abdominal pain, malaise, headache, dizziness, mental confusion, disorientation, and possible hallucinations.
n6:hasAHFSCode
n26:08-16-04
n3:foodInteraction
Take with food to reduce irritation.
n3:proteinBinding
20-30%
n3:salt
n3:synthesisReference
Sang-Woo Park, "Preparation of ethambutol-diisoniazide methane sulfonic acid salt." U.S. Patent US4450274, issued February, 1973.
n17:hasConcept
n18:M0007814
foaf:page
n20:ethambutol.html n24:ethambutol.htm
n3:IUPAC-Name
n5:271B5659-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B565F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B565E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B565B-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B565C-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B565D-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B5657-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B5655-363D-11E5-9242-09173F13E4C5 n5:271B5658-363D-11E5-9242-09173F13E4C5 n5:271B5670-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B5656-363D-11E5-9242-09173F13E4C5
n6:hasATCCode
n7:J04AK02
n3:H-Bond-Acceptor-Count
n5:271B5665-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B5666-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B5660-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B5661-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B5663-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B5662-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B5664-363D-11E5-9242-09173F13E4C5
n3:absorption
About 75% to 80% of an orally administered dose of ethambutol is absorbed from the gastrointestinal tract.
n3:affectedOrganism
Humans and other mammals Mycobacterium tuberculosis
n3:casRegistryNumber
74-55-5
n3:category
n3:containedIn
n15:271B564F-363D-11E5-9242-09173F13E4C5 n15:271B5650-363D-11E5-9242-09173F13E4C5 n15:271B564D-363D-11E5-9242-09173F13E4C5 n15:271B564E-363D-11E5-9242-09173F13E4C5 n15:271B564C-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B566B-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B566D-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B566E-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B566F-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B566A-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B5669-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B566C-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B565A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B5667-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B5668-363D-11E5-9242-09173F13E4C5